asco.org3 天
Choosing Wisely
The American Society of Clinical Oncology (ASCO) is a medical professional oncology society committed to conquering cancer through research, education, prevention, and delivery of high-quality patient ...
asco.org3 天
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Real-world data on treatment patterns of advanced CRC in third-line and beyond.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org6 天
ASCO's Advocacy Toolkit
The Association for Clinical Oncology (ASCO) offers multiple ways for you and your colleagues to engage with policymakers and educate them on ASCO’s advocacy priorities, while leveraging your insights ...
asco.org5 天
Expression of PD-L1 and IDO in hormone receptor negative DCIS.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Cisplatin (Cis) combined with sintilimab (Sint) and niraparib (Nir) in advanced solid ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Stakeholder evaluation of a supportive care needs assessment tool for adolescent and young ...
Navigating resources associated with school (e.g., talking with advisors, using a disability office) Navigating resources associated with work (e.g., discrimination due to diagnosis, accessing ...
asco.org5 天
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A ...
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org4 天
Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5 天
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2 ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...